Early 2008 was notable for the publication of a number of smaller clinical trials and larger meta-analyses that further establish the benefit of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in reducing cardiovascular risk. It was a trial of a newer class of drugs, the cholesterol absorption inhibitors, however, which stimulated the most conversation and controversy.
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The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study was a randomized, double-blind, placebo-controlled study [1 ] designed to examine the impact of ezetimibe on a baseline of aggressive statin therapy in 720 patients with familial hypercholesterolemia. The authors selected the primary endpoint of change in carotid-artery intima-media thickness as assessed by B-mode ultrasonography, a perceived surrogate for cardiovascular events [2 ] . Despite finding a statistically significant 16.5% difference in LDL cholesterol reduction and a 25.7% difference in C-reactive protein reduction in ezetimibe-treated patients (both P < 0.01), there was no significant impact on atherosclerotic progression (P ¼ 0.29). Outside the controversy regarding the timeliness with which these results were reported, there have been several topics of debate, including whether the mechanism by which LDL is lowered is important in affecting outcome as well as the role of surrogate endpoints in trial design.
On the basis of the favorable results of a multitude of well designed and executed clinical trials, statin use has become ubiquitous in patients with cardiovascular disease. Despite this fact, nearly one third of patients within the first year of initiation and up to one half by 5 years discontinue therapy [3] , with a number of these related to drug intolerance. As a result, newer drug classes have been sought. Ezetimibe was initially heralded for its novel mechanism, the inhibition of cholesterol absorption, theoretically obviating hepatic and muscular toxicities [4 ] . Recent studies, however, have questioned ezetimibe's true target [5] and whether systemic toxicities may occur [6] . Studies have demonstrated consistent reductions in LDL cholesterol and short-term tolerance and as a result, over 15% of prescriptions for lipid-lowering drugs in the USA in 2006 were for ezetimibe [7 ] . Despite early Food and Drug Administration (FDA) approval, however, clinical outcomes data remain lacking. There is hope that the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a randomized clinical study of 18 000 patients comparing ezetimibe/simvastatin with simvastatin alone in patients with acute coronary syndrome [8], will provide greater insight. While awaiting these results, an accompanying editorial to ENHANCE recommends first the use of statins and second adjunctive agents with established clinical benefits when added to statins (including nicotinic acid, fibrates and bile acid sequestrants) before considering ezetimibe [9] .
Although mortality or composite mortality, myocardial infarction and stroke are the least subjective and most applicable outcomes for clinical practice, such trials require large patient populations and prolonged followup, leading to higher costs and delayed results. The use of surrogate endpoints in trial design has consequently grown. Invasive and noninvasive assessments of coronary and noncoronary vascular plaque burden as well as serum markers of inflammation appear to be associated with increased cardiovascular risk. What remains unknown, however, is whether modifying these findings will translate into improved clinical outcomes. From the ENHANCE study, therefore, it remains uncertain whether ezetimibe is ineffective in modifying risk or whether change in carotid intima-media thickness is simply a flawed endpoint. For now, the results of such trials should remain subject to healthy skepticism. The ENHANCE study failed to show any additional benefit of the cholesterol absorption inhibitor ezetimibe on carotid intima-medial thickness progression despite improvements in LDL cholesterol (16.5% reduction) and C-reactive protein (25.7% reduction) in this randomized, double-blind placebo-controlled study of statin-treated patients. Although no hard endpoints could be examined because of the small sample size (720 patients) and short duration of follow-up (2 years), a number of different interpretations of the results have occurred and generated significant controversy. 
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